Capivasertib Combination Therapy in Advanced Breast Cancer and Other Solid Tumors: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Biomarker-Defined Outcomes

Background

Capivasertib is an oral pan-AKT inhibitor evaluated in combination with multiple systemic therapies across solid tumors, but its efficacy and safety vary by disease setting, biomarker status, and treatment backbone. We aimed to systematically evaluate the efficacy, safety, and early-phase clinical activity of capivasertib-containing combination regimens in advanced breast cancer and other solid tumors.